Composition Comprising a Rapalog and a Radiolabelled Gastrin Analogue, in Particular for Use in the Treatment And/or Diagnosis of Cckb Receptor Positive Cancer or Tumors

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses a pharmaceutical composition that combines a rapalog (such as rapamycin or its analogues) with a radiolabeled gastrin analogue. This combination is specifically designed for the treatment and/or diagnosis of cancers or tumors that express the cholecystokinin B receptor (CCKBR), such as medullary thyroid cancer (MTC), gliomas, gastrointestinal neuroendocrine tumors, and several others. Administration of the rapalog increases the expression of CCKBR in tumor cells, which enhances the uptake of the radiolabeled gastrin analogue into the tumor tissue, resulting in more efficient delivery of radiation to tumors while minimizing exposure to healthy tissues.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted therapy for CCKB receptor positive tumors such as medullary thyroid cancer, gliomas, GEP-NETs, astrocytomas, stomach, colon, ovarian, or breast cancers.
• Radio-diagnostic imaging for identifying and monitoring CCKBR-positive tumors using radiolabeled gastrin analogues.
• Combination with other chemotherapeutic or immunomodulatory agents to enhance cancer treatment effectiveness in patients with CCKBR-positive tumors.
• Theranostic approaches (combined therapy and diagnostics) for personalized cancer treatment.

BenefitsContent extracted from patent full text and abstract with AI.

• Enhanced uptake of radiolabeled therapeutic agents specifically in tumor cells, improving efficacy of treatment.
• Reduced accumulation of radioactive compounds in healthy tissues, minimizing cytotoxic side effects and increasing patient safety.
• Potential for both diagnosis and treatment (theranostics) in a single protocol.
• Applicable to a variety of CCKBR-positive tumors, increasing its clinical utility for rare and common cancers.
• Flexible administration schedules (simultaneous or sequential), which can be tailored to patient needs.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a composition comprising (i) rapamycin and/or a rapalog and (ii) a radiolabeled gastrin analogue. The composition of the present invention can be used for the treatment and/or diagnosis of CCKB receptor positive cancer or tumors and leads to superior tumor uptake of radiolabeled gastrin analogue, resulting in improved delivery and therapeutic efficacy while cytotoxic side-effects are prevented and/or reduced.